J. H. Bourhis

1.0k total citations
35 papers, 507 citations indexed

About

J. H. Bourhis is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, J. H. Bourhis has authored 35 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 10 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in J. H. Bourhis's work include Multiple Myeloma Research and Treatments (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Immune Cell Function and Interaction (5 papers). J. H. Bourhis is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Hematopoietic Stem Cell Transplantation (6 papers) and Immune Cell Function and Interaction (5 papers). J. H. Bourhis collaborates with scholars based in France, United States and Italy. J. H. Bourhis's co-authors include J L Pico, Pierre Fenaux, Serge Koscielny, T. Girinski, Christian Denier, Olivier Hartmann, Sylvie Chevret, J. Leclère, Dawn W. Adams and A. Aupérin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

J. H. Bourhis

34 papers receiving 493 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. H. Bourhis France 12 281 148 117 78 74 35 507
Yoshihisa Morishita Japan 12 210 0.7× 104 0.7× 132 1.1× 59 0.8× 50 0.7× 36 414
Murat Tombuloğlu Türkiye 11 231 0.8× 87 0.6× 83 0.7× 27 0.3× 78 1.1× 63 453
Aarthi Shenoy United States 13 327 1.2× 93 0.6× 189 1.6× 71 0.9× 117 1.6× 41 649
Prentice Hg United Kingdom 14 354 1.3× 87 0.6× 177 1.5× 117 1.5× 145 2.0× 20 622
Chiara Nozzoli Italy 14 369 1.3× 185 1.3× 200 1.7× 34 0.4× 73 1.0× 40 528
Sharon Abish Canada 13 132 0.5× 87 0.6× 124 1.1× 65 0.8× 114 1.5× 23 539
Carl E. Krill United States 14 123 0.4× 202 1.4× 121 1.0× 121 1.6× 73 1.0× 24 612
HM Lazarus United States 6 305 1.1× 89 0.6× 143 1.2× 156 2.0× 71 1.0× 7 461
RA Krance United States 10 423 1.5× 89 0.6× 119 1.0× 147 1.9× 75 1.0× 16 636
Makoto Yazaki Japan 13 269 1.0× 116 0.8× 106 0.9× 139 1.8× 203 2.7× 33 547

Countries citing papers authored by J. H. Bourhis

Since Specialization
Citations

This map shows the geographic impact of J. H. Bourhis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. H. Bourhis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. H. Bourhis more than expected).

Fields of papers citing papers by J. H. Bourhis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. H. Bourhis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. H. Bourhis. The network helps show where J. H. Bourhis may publish in the future.

Co-authorship network of co-authors of J. H. Bourhis

This figure shows the co-authorship network connecting the top 25 collaborators of J. H. Bourhis. A scholar is included among the top collaborators of J. H. Bourhis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. H. Bourhis. J. H. Bourhis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sadowska‐Klasa, Alicja, Jan Maciej Zaucha, Myriam Labopin, et al.. (2024). Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry. Bone Marrow Transplantation. 59(3). 387–394.
2.
Nanbakhsh, Arash, Cécile Pochon, Sophie Amsellem, et al.. (2014). Enhanced Cytotoxic Activity of Ex Vivo-differentiated Human Natural Killer Cells in the Presence of HOXB4. Journal of Immunotherapy. 37(5). 278–282. 3 indexed citations
3.
4.
Kiladjian, Jean‐Jacques, Gian Paolo Visentin, Sylvie Chevret, et al.. (2008). Activation of cytotoxic T-cell receptor    T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica. 93(3). 381–389. 30 indexed citations
5.
Jabbour, Elias, Serge Koscielny, Catherine Sebban, et al.. (2006). High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia. 20(5). 814–819. 25 indexed citations
6.
Bourhis, J. H.. (2004). LA CASPOFUNGINE DANS LE TRAITEMENT EMPIRIQUE DES INFECTIONS FONGIQUES. Journal de Mycologie Médicale. 14(4). 240–243. 1 indexed citations
7.
Ribrag, Vincent, Florence Suzan, Christophe Ravoet, et al.. (2003). Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts. Leukemia. 17(2). 319–322. 5 indexed citations
8.
Ribrag, Vincent, Serge Koscielny, J Vantelon, et al.. (2003). Phase II Trial of Irinotecan (CPT-11) in Relapsed or Refractory Non-Hodgki n's Lymphomas. Leukemia & lymphoma. 44(9). 1529–1533. 11 indexed citations
9.
10.
Fenaux, Pierre, J. H. Bourhis, & Vincent Ribrag. (2001). Burkitt's Acute Lymphocytic Leukemia (L3ALL) in Adults. Hematology/Oncology Clinics of North America. 15(1). 37–50. 8 indexed citations
11.
Girinsky, T., E Benhamou, J. H. Bourhis, et al.. (2001). Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies. Cancer/Radiothérapie. 5(1). 96–97. 1 indexed citations
12.
Lassau, Nathalie, J. Leclère, A. Aupérin, et al.. (1997). Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients.. Radiology. 204(2). 545–552. 87 indexed citations
13.
Gautier, Élodie, et al.. (1997). Parvovirus B19 associated neutropenia. Treatment with Rh G-CSF. PubMed. 39(2). 85–87. 7 indexed citations
14.
Marit, Gérald, C. Fabères, J L Pico, et al.. (1996). Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma.. Journal of Clinical Oncology. 14(4). 1306–1313. 26 indexed citations
15.
Bonnotte, Bernard, Cécile Pardoux, J. H. Bourhis, et al.. (1996). Inhibition of the human allogeneic mixed lymphocyte response by cyclosporin A: relationship with the IL‐12 pathway. Tissue Antigens. 48(4). 265–270. 8 indexed citations
16.
Landman‐Parker, Judith, Gèrard Socié, Thierry Petit, et al.. (1994). Detection of recipient cells after non T-cell depleted bone marrow transplantation for leukemia by PCR amplification of minisatellites or of a Y chromosome marker has a different prognostic value.. PubMed. 8(11). 1989–94. 12 indexed citations
17.
Bourhis, J. H., Françoise Beaujean, Patrice Viens, et al.. (1993). High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. European Journal of Cancer. 29(10). 1398–1403. 23 indexed citations
18.
Pico, J. L., et al.. (1993). Escalating High-Dose Carboplatin and Autologous Bone Marrow Transplantation in Solid Tumors. Oncology. 50(2). 47–52. 14 indexed citations
19.
Dennig, Dieter, Salaheddine Mécheri, J. H. Bourhis, & Michael K. Hoffman. (1992). Interleukin-2 may enhance or inhibit antibody production by B cells depending on intracellular cAMP concentrations.. PubMed. 77(2). 251–5. 7 indexed citations
20.
Keever, C, Karen Pekle, M. V. Gazzola, et al.. (1989). Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.. The Journal of Immunology. 143(10). 3241–3249. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshihisa Morishita Breakdown of academic impact, for papers by Murat Tombuloğlu Breakdown of academic impact, for papers by Aarthi Shenoy Breakdown of academic impact, for papers by Prentice Hg Breakdown of academic impact, for papers by Chiara Nozzoli Breakdown of academic impact, for papers by Sharon Abish Breakdown of academic impact, for papers by Carl E. Krill Breakdown of academic impact, for papers by HM Lazarus Breakdown of academic impact, for papers by RA Krance Breakdown of academic impact, for papers by Makoto Yazaki
Rankless by CCL
2026